Amylyx Pharmaceuticals, Inc. AMLX R2K
Company Overview
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -33.3%, profit CAGR 9.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -33.33% |
| 1 Year: | -100.00% |
Compounded Profit Growth
| 5 Years: | 9.01% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +111.41% |
| 6 Months: | +43.50% |
| 3 Months: | +5.08% |
| 1 Month: | +21.86% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.96 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -33.3% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AMLX Amylyx Pharmaceuticals, Inc. R2K | 17.78 | -12.01 | $1.98B | 0.00% | -49.46% | -63.26% | -33.33% | 9.01% |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 345.00K | 71.43M | 98.22M | 102.69M | 88.64M | -1.02M | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 37.80M | 42.86M | 36.03M | 36.60M | 43.78M |
| Operating Income | -12.87M | -18.59M | -22.92M | -47.81M | -54.25M | -54.68M | -2.05M | 20.20M | 18.72M | -122.13M | -76.29M | - | - | -37.80M | -42.86M | -36.03M | -36.60M | -43.78M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -37.65M | -42.72M | -35.91M | -36.50M | -43.68M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -35.91M | -41.44M | -34.39M | -32.95M | -41.28M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | -635.00K | 0 | 0 | 0 | 46.00K | - |
| Net Income | -14.52M | -21.92M | -23.14M | -47.85M | -54.07M | -53.76M | 1.57M | 22.07M | 20.89M | -118.79M | -72.70M | - | - | -35.91M | -41.44M | -34.39M | -33.00M | -41.28M |
| Diluted EPS | - | -3.41 | -3.42 | -0.93 | -0.93 | -0.92 | 0.02 | 0.31 | 0.30 | -1.75 | -1.07 | - | - | -0.42 | -0.46 | -0.37 | -0.30 | -0.37 |
| R&D Expense | 6.86M | 10.93M | 12.85M | 21.46M | 24.26M | 24.91M | 24.19M | 29.04M | 30.04M | 36.61M | 23.35M | 21.24M | - | 22.12M | 27.22M | 19.86M | - | 27.61M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 22.23M | 380.79M | 87.37M | 0 |
| Cost of Revenue | - | 2.99M | 25.44M | 124.63M | 0 |
| Gross Profit | - | 19.24M | 355.35M | -37.26M | 0 |
| Operating Expenses | - | 220.58M | 316.54M | 218.41M | 153.29M |
| Operating Income | - | -201.34M | 38.80M | -255.68M | -153.29M |
| EBITDA | - | -200.85M | 39.89M | -254.77M | -152.77M |
| Interest Expense | 0 | - | - | - | - |
| Pretax Income | - | -197.60M | 54.30M | -302.14M | -144.69M |
| Tax Provision | - | 774.00K | 5.03M | -393.00K | 46.00K |
| Net Income | - | -198.38M | 49.27M | -301.74M | -144.74M |
| Diluted EPS | - | -3.39 | 0.70 | -4.43 | -1.53 |
| R&D Expense | 44.04M | 93.45M | 128.19M | 104.08M | 90.40M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 391.45M | 517.45M | 193.63M | 332.64M |
| Current Assets | - | - | 382.13M | 464.67M | 189.43M | 323.67M |
| Cash & Equivalents | - | - | 62.53M | 170.20M | 77.39M | 226.65M |
| Inventory | - | 0 | 9.77M | 38.32M | 0 | - |
| Receivables | - | - | 15.31M | 40.05M | 447.00K | 88.00K |
| Total Liabilities | - | - | 50.85M | 84.02M | 28.87M | 27.39M |
| Current Liabilities | - | - | 46.61M | 82.04M | 28.41M | 22.69M |
| Long Term Debt | - | - | - | - | - | - |
| Total Debt | - | - | 6.28M | 4.24M | 1.98M | 5.96M |
| Total Equity | -66.72M | - | 340.61M | 433.43M | 164.76M | 305.26M |
| Shares Outstanding | - | - | 66.51M | 67.71M | 68.63M | 109.88M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -179.87M | 11.92M | -167.65M | -123.34M |
| Investing Cash Flow | - | -238.99M | 92.05M | 75.65M | 14.04M |
| Financing Cash Flow | - | 431.79M | 3.54M | 348.00K | 257.03M |
| Capital Expenditure | - | -2.53M | -1.24M | -157.00K | -138.00K |
| Free Cash Flow | - | -182.40M | 10.68M | -167.80M | -123.48M |
| Net Change in Cash | - | 12.93M | 107.52M | -91.64M | 147.72M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 86.5% | 93.3% | -42.6% | - |
| Operating Margin % | - | -905.7% | 10.2% | -292.6% | - |
| Net Margin % | - | -892.4% | 12.9% | -345.4% | - |
| ROE % | - | -58.2% | 11.4% | -183.1% | -47.4% |
| ROCE % | - | -58.4% | 8.9% | -154.7% | -49.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.96% | 16.63M | $302.68M |
| 2 | Blackrock Inc. | 7.94% | 8.83M | $160.68M |
| 3 | Perceptive Advisors Llc | 7.45% | 8.28M | $150.78M |
| 4 | TCG Crossover Management, LLC | 5.62% | 6.24M | $113.64M |
| 5 | Commodore Capital Lp | 5.08% | 5.65M | $102.83M |
| 6 | Janus Henderson Group PLC | 4.48% | 4.99M | $90.75M |
| 7 | Saturn V Capital Management LP | 3.91% | 4.35M | $79.17M |
| 8 | Vanguard Capital Management LLC | 3.72% | 4.14M | $75.38M |
| 9 | Adage Capital Partners GP L.L.C. | 3.20% | 3.56M | $64.81M |
| 10 | First Light Asset Management, LLC | 2.87% | 3.19M | $58.07M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AMLX
Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight
Recently published Post-Bariatric Hypoglycemia Market Insights report includes a comprehensive understanding of current treatment practices, post-bariatric hypoglycemia emerging drugs, market share of individual therapies, and current and f…
Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data?
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is one of the best low-priced pharma stocks on this list. TheFly reported on June 25 that Guggenheim raised its…
Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
CAMBRIDGE, Mass., June 23, 2026--Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape
Amylyx Pharmaceuticals (NASDAQ:AMLX) Co-Chief Executive Officer Justin Klee said the company is preparing for a key Phase 3 readout for avexitide, its lead program for post-bariatric hypoglycemia, during an appearance at the Goldman Sachs G…
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
CAMBRIDGE, Mass., June 08, 2026--Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Its Recent Share Price Rebound
Why Amylyx Pharmaceuticals (AMLX) Is Drawing Attention Now Amylyx Pharmaceuticals (AMLX) is back on many investors’ radars after recent trading, as the stock’s mixed near term performance contrasts with its longer term returns and current v…
AMLX — Frequently Asked Questions
What is the current share price of Amylyx Pharmaceuticals, Inc. (AMLX)?
As of 2026-07-15 16:51 PDT, Amylyx Pharmaceuticals, Inc. (AMLX) trades at $17.78 on NasdaqGS. Its 52-week range is $7.64 to $18.70.
What is the market capitalisation of AMLX?
Amylyx Pharmaceuticals, Inc. (AMLX) has a market capitalisation of $1.98B on NasdaqGS.
What is the P/E ratio of AMLX?
AMLX trades at a trailing price-to-earnings (P/E) ratio of -12.01. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 7.40.
What is the return on equity (ROE) of AMLX?
AMLX has a return on equity (ROE) of -63.26%. Its return on capital employed (ROCE) is -49.46%.
Is AMLX a good stock to buy?
This page provides a data-driven analysis of Amylyx Pharmaceuticals, Inc. (AMLX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.